ClinicalTrials.gg
TerminatedNCT04035668LOUiSSeUpdated Jan 30, 2023Results posted

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

A Phase 2 interventional study of Remibrutinib and Placebo in Sjögren Syndrome, sponsored by Novartis Pharmaceuticals. Terminated at 26 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
10th of 14
73 · median 240
Started
2019
with 1 other
Phase 2
9 of 15
1 open now
Registered
5th of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 5th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.

Read the detailed description

This study was planned as an adaptive Phase 2 randomized, double-blind, placebo-controlled, multi-center, integrated dose-ranging study to evaluate the safety and efficacy of multiple remibrutinib doses in patients with moderate to severe Sjögren's Syndrome.

Of the initially planned two parts, only Part 1 of the study was conducted. In Part 1, the highest expected biologically active single dose of remibrutinib (100 mg) was tested in two different dosing regimens, a once daily dose (qd) or twice daily dose (bid), and compared to the placebo group. Each patient in Part 1 of the study underwent a screening period of up to 6 weeks, a treatment period of 24 weeks, and a follow-up period of 30 days post-treatment before the End of Study (EOS) visit. The total duration for each patient in the study, including Screening, was up to 35 weeks. For the treatment period, patients were randomized in a 1:1:1 ratio to one of the 3 treatment groups: remibrutinib 100 mg bid, remibrutinib 100 mg qd and placebo.

03

Conditions studied

  • Sjögren Syndrome

Keywords

  • LOU064
  • remibrutinib
  • Sjogren Syndrome
  • Dry Eye Syndromes
  • Pathological Processes
  • Arthritis
  • Joint Diseases
  • Musculoskeletal Diseases
  • Rheumatic Diseases
  • Xerostomia
  • Salivary Gland Diseases
  • Mouth Diseases
  • Stomatognathic Diseases
  • Lacrimal Apparatus Diseases
  • Eye Diseases
  • Connective Tissue Diseases
  • Autoimmune Diseases
  • Immune System Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SjS according to the 2016 ACR/EULAR criteria
  • Screening ESSDAI (based on weighted score) ≥ 5 derived from 8 domains
  • Screening ESSPRI ≥ 5
  • Seropositive for anti-Ro/SSA antibodies at or within 3 months prior to screening
  • Unstimulated salivary flow > 0 mL/min.

Exclusion criteria

Exclusion Criteria:

  • Sjögren's Syndrome overlap syndromes with another disease as primary illness
  • DMARDs or kinase inhibitors within 3 months prior to baseline above certain doses OR maintained during study
  • Rituximab or other B cell depleting drug within 12 months of Screening .
  • Current use of prednisone or equivalent > 15mg/d or dose change within 2 weeks prior to Screening
  • Use of medication known to cause, as a major side effect, dry mouth / eyes
  • , , , known or suspected history of an ongoing, chronic or recurrent infectious disease such as tuberculosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Remibrutinib 100 mg bid

    Remibrutinib 100 mg twice daily (bid)

    Drug: Remibrutinib

  • Experimental
    Remibrutinib 100 mg qd

    Remibrutinib 100 mg once daily (qd)

    Drug: Remibrutinib · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo group

    Drug: Placebo

Interventions

  • Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.

    Also known as: LOU064

  • DrugPlacebo

    Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24

    ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in ESSDAI Total Score Over Time

    ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20

  2. Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Total Score Over Time

    ESSPRI is an established disease outcome measure for Sjögren's Syndrome. It consists of three domains of dryness, pain, and fatigue. The patient can assess the severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain +fatigue) /3. ESSPRI total score ranges from 0 to 10 with higher values indicating more disease symptoms. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSPRI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24

  3. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Total Score Over Time

    FACIT-F v4 is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). FACIT-F total score ranges from 0 to 52 with higher values indicating higher quality of life (less fatigue). A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in FACIT-F for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24

  4. Change From Baseline in EuroQual 5 Dimensions (EQ-5D) VAS Score Over Time

    EQ-5D is a standardized instrument that measures the health-related quality of life. The EQ-5D consists of a descriptive system and a visual analog scale (VAS).The EQ-5D VAS records the patient's self-rated health on a vertical visual analogue scale with 0 representing 'Worst imaginable Health State' and 100 'Best imaginable Health State'. A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in EQ-5D VAS score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24

  5. Change From Baseline in Physician Global Assessment Scale (PhGA) Score Over Time

    The physician's global assessment scale was used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from "no disease activity" (0) to "maximal disease activity" (100). A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in PhGA score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Number of participants with TEAEs and serious TEAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as TEAEs. TEAEs are defined as adverse events that started after the first dose of study medications or adverse events present prior to start of double-blind treatment but increased in severity. The number of participants in each category is reported in the table.

    Time frame: From first dose of study treatment up 30 days after last dose (Week 29)

  7. Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4

  8. Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24

  9. Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 4

    Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4

  10. Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 24

    Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24

  11. Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4

  12. Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24

  13. Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4

  14. Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24

  15. Elimination Half-life (T1/2) of Remibrutinib at Week 4

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4

  16. Elimination Half-life (T1/2) of Remibrutinib at Week 24

    Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24

07

Results

Posted Dec 20, 2022

Participant flow

Participants took part in 26 investigative sites in 12 countries.

Participant flow — Overall Study
MilestoneRemibrutinib 100 mg BidRemibrutinib 100 mg qdPlacebo
Started242524
Completed171721
Not completed783
Withdrew: Adverse event342
Withdrew: Lost to follow-up010
Withdrew: Physician decision211
Withdrew: Subject decision220

Outcome measures

PrimaryChange From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24

ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Total Score at Week 24-4.70 ± 0.78-3.70 ± 0.80-4.20 ± 0.56-1.34 ± 0.74
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.002 (one-sided p-value) · Mean difference (final values): -2.86 · 95% CI -4.71 to -1.01Difference (Any remibrutinib - Placebo)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -1.00 · 95% CI -3.24 to 1.25Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryChange From Baseline in ESSDAI Total Score Over Time

ESSDAI is a validated disease outcome measure for Sjögren's Syndrome. The instrument contains 12 organ-specific domains contributing to disease activity: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological and biological. For each domain, features of disease activity were scored according to their severity. These scores were summed across the 12 domains in a weighted manner to provide the total score. ESSDAI total score ranges from 0 to 123 with higher values indicating more disease activity. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSDAI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
Reported as:
Least squares mean · score on scale
Change From Baseline in ESSDAI Total Score Over Time
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Week 2-1.68 ± 0.52-1.05 ± 0.52-1.37 ± 0.37-0.37 ± 0.55
Week 4-2.57 ± 0.60-2.54 ± 0.62-2.55 ± 0.43-0.79 ± 0.61
Week 8-2.74 ± 0.72-2.93 ± 0.71-2.83 ± 0.51-2.36 ± 0.69
Week 12-3.66 ± 0.74-2.56 ± 0.75-3.11 ± 0.53-1.92 ± 0.73
Week 16-4.02 ± 0.71-2.57 ± 0.74-3.29 ± 0.51-2.16 ± 0.69
Week 20-4.40 ± 0.73-3.26 ± 0.75-3.83 ± 0.52-1.84 ± 0.69
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.065 (one-sided p-value) · Mean difference (final values): -0.99 · 95% CI -2.29 to 0.30Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.010 (one-sided p-value) · Mean difference (final values): -1.76 · 95% CI -3.24 to -0.29Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.289 (one-sided p-value) · Mean difference (final values): -0.47 · 95% CI -2.17 to 1.22Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.093 (one-sided p-value) · Mean difference (final values): -1.19 · 95% CI -2.97 to 0.59Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.094 (one-sided p-value) · Mean difference (final values): -1.13 · 95% CI -2.84 to 0.57Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.012 (one-sided p-value) · Mean difference (final values): -1.99 · 95% CI -3.71 to -0.28
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.63 · 95% CI -2.10 to 0.84Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.03 · 95% CI -1.75 to 1.69Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 0.19 · 95% CI -1.83 to 2.21Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -1.10 · 95% CI -3.20 to 1.01Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -1.45 · 95% CI -3.50 to 0.60Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -1.14 · 95% CI -3.22 to 0.95Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryChange From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Total Score Over Time

ESSPRI is an established disease outcome measure for Sjögren's Syndrome. It consists of three domains of dryness, pain, and fatigue. The patient can assess the severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain +fatigue) /3. ESSPRI total score ranges from 0 to 10 with higher values indicating more disease symptoms. A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in ESSPRI for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Total Score Over Time
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Week 2-0.44 ± 0.260.18 ± 0.26-0.13 ± 0.18-0.09 ± 0.27
Week 4-0.72 ± 0.30-0.14 ± 0.30-0.43 ± 0.21-0.35 ± 0.30
Week 8-0.83 ± 0.31-0.38 ± 0.31-0.60 ± 0.22-0.57 ± 0.29
Week 12-0.88 ± 0.31-0.32 ± 0.31-0.60 ± 0.22-0.66 ± 0.29
Week 16-0.77 ± 0.36-0.39 ± 0.37-0.58 ± 0.26-0.71 ± 0.34
Week 20-0.92 ± 0.38-0.74 ± 0.39-0.83 ± 0.27-0.92 ± 0.36
Week 24-1.17 ± 0.34-0.76 ± 0.35-0.96 ± 0.24-1.13 ± 0.31
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.460 (one-sided p-value) · Mean difference (final values): -0.03 · 95% CI -0.69 to 0.62Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.418 (one-sided p-value) · Mean difference (final values): -0.08 · 95% CI -0.82 to 0.66Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.466 (one-sided p-value) · Mean difference (final values): -0.03 · 95% CI -0.76 to 0.70Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.560 (one-sided p-value) · Mean difference (final values): 0.06 · 95% CI -0.67 to 0.79Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.616 (one-sided p-value) · Mean difference (final values): 0.13 · 95% CI -0.73 to 0.99Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.581 (one-sided p-value) · Mean difference (final values): 0.13 · 95% CI -0.81 to 0.99
  • Any Remibrutinib vs Placebo · MMRM · p = 0.663 (one-sided p-value) · Mean difference (final values): 0.17 · 95% CI -0.62 to 0.96Difference (Any remibrutinib - Placebo)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.62 · 95% CI -1.35 to 0.11Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.58 · 95% CI -1.42 to 0.26Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.45 · 95% CI -1.31 to 0.42Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.57 · 95% CI -1.44 to 0.31Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.37 · 95% CI -1.39 to 0.65Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.37 · 95% CI -1.39 to 0.65Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.40 · 95% CI -1.37 to 0.57Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Total Score Over Time

FACIT-F v4 is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). FACIT-F total score ranges from 0 to 52 with higher values indicating higher quality of life (less fatigue). A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in FACIT-F for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Total Score Over Time
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Week 21.80 ± 1.32-0.51 ± 1.350.64 ± 0.953.37 ± 1.43
Week 44.83 ± 1.503.97 ± 1.574.40 ± 1.093.51 ± 1.58
Week 84.00 ± 1.643.79 ± 1.663.90 ± 1.175.26 ± 1.60
Week 124.88 ± 1.804.25 ± 1.864.56 ± 1.307.30 ± 1.77
Week 164.40 ± 1.973.29 ± 2.083.84 ± 1.447.73 ± 1.98
Week 2010.01 ± 2.204.32 ± 2.307.16 ± 1.605.77 ± 2.17
Week 248.17 ± 2.454.64 ± 2.556.40 ± 1.777.45 ± 2.32
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.940 (one-sided p-value) · Mean difference (final values): -2.73 · 95% CI -6.18 to 0.73Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.322 (one-sided p-value) · Mean difference (final values): 0.89 · 95% CI -2.95 to 4.74Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.753 (one-sided p-value) · Mean difference (final values): -1.36 · 95% CI -5.32 to 2.59Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.891 (one-sided p-value) · Mean difference (final values): -2.74 · 95% CI -7.13 to 1.66Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.941 (one-sided p-value) · Mean difference (final values): -3.88 · 95% CI -8.77 to 1.01Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.304 (one-sided p-value) · Mean difference (final values): 1.39 · 95% CI -4.01 to 6.79
  • Any Remibrutinib vs Placebo · MMRM · p = 0.640 (one-sided p-value) · Mean difference (final values): -1.05 · 95% CI -6.89 to 4.79Difference (Any remibrutinib - Placebo)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 2.32 · 95% CI -1.44 to 6.07Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 0.86 · 95% CI -3.46 to 5.18Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 0.20 · 95% CI -4.43 to 4.83Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 0.63 · 95% CI -4.53 to 5.78Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 1.11 · 95% CI -4.60 to 6.82Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 5.69 · 95% CI -0.66 to 12.04Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 3.53 · 95% CI -3.53 to 10.59Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryChange From Baseline in EuroQual 5 Dimensions (EQ-5D) VAS Score Over Time

EQ-5D is a standardized instrument that measures the health-related quality of life. The EQ-5D consists of a descriptive system and a visual analog scale (VAS).The EQ-5D VAS records the patient's self-rated health on a vertical visual analogue scale with 0 representing 'Worst imaginable Health State' and 100 'Best imaginable Health State'. A positive change from baseline is a favorable outcome. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in EQ-5D VAS score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in EuroQual 5 Dimensions (EQ-5D) VAS Score Over Time
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Week 2-3.05 ± 3.11-2.86 ± 3.16-2.95 ± 2.22-3.02 ± 3.28
Week 4-1.74 ± 2.71-0.03 ± 2.86-0.88 ± 1.972.99 ± 2.87
Week 81.46 ± 3.201.76 ± 3.201.61 ± 2.263.44 ± 3.04
Week 12-2.36 ± 2.711.58 ± 2.82-0.39 ± 1.954.00 ± 2.64
Week 16-0.44 ± 3.274.27 ± 3.541.92 ± 2.411.79 ± 3.28
Week 20-0.91 ± 3.155.37 ± 3.332.23 ± 2.295.29 ± 3.01
Week 241.81 ± 3.475.73 ± 3.653.77 ± 2.522.07 ± 3.22
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.494 (one-sided p-value) · Mean difference (final values): 0.06 · 95% CI -7.84 to 7.96Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.866 (one-sided p-value) · Mean difference (final values): -3.87 · 95% CI -10.81 to 3.06Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.684 (one-sided p-value) · Mean difference (final values): -1.82 · 95% CI -9.37 to 5.73Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.908 (one-sided p-value) · Mean difference (final values): -4.39 · 95% CI -10.93 to 2.14Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.487 (one-sided p-value) · Mean difference (final values): 0.13 · 95% CI -8.00 to 8.26Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.790 (one-sided p-value) · Mean difference (final values): -3.06 · 95% CI -10.61 to 4.49
  • Any Remibrutinib vs Placebo · MMRM · p = 0.340 (one-sided p-value) · Mean difference (final values): 1.70 · 95% CI -6.48 to 9.88Difference (Any remibrutinib - Placebo)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.19 · 95% CI -9.06 to 8.68Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -1.71 · 95% CI -9.59 to 6.17Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.30 · 95% CI -9.34 to 8.74Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -3.94 · 95% CI -11.74 to 3.86Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -4.71 · 95% CI -14.34 to 4.93Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -6.29 · 95% CI -15.44 to 2.87Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -3.92 · 95% CI -14.01 to 6.16Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryChange From Baseline in Physician Global Assessment Scale (PhGA) Score Over Time

The physician's global assessment scale was used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from "no disease activity" (0) to "maximal disease activity" (100). A negative change from baseline indicates improvement. The baseline value is defined as the last assessment performed prior to administration of the first dose of study treatment. A mixed effect model for repeated measurements (MMRM) was fitted to the changes from baseline in PhGA score for all post-baseline time points up to Week 24. Values estimated from the model are presented in this table.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in Physician Global Assessment Scale (PhGA) Score Over Time
score on scaleRemibrutinib 100 mg qdRemibrutinib 100 mg BidAny RemibrutinibPlacebo
Week 2-4.21 ± 2.90-4.02 ± 2.85-4.12 ± 2.04-4.82 ± 3.10
Week 4-9.58 ± 2.89-8.93 ± 2.96-9.26 ± 2.08-7.28 ± 2.95
Week 8-13.68 ± 3.39-13.78 ± 3.28-13.73 ± 2.37-13.23 ± 3.16
Week 12-13.85 ± 3.63-9.45 ± 3.68-11.65 ± 2.60-17.67 ± 3.52
Week 16-19.37 ± 3.61-7.25 ± 3.74-13.31 ± 2.61-15.90 ± 3.51
Week 20-23.56 ± 3.43-17.31 ± 3.48-20.43 ± 2.45-17.57 ± 3.20
Week 24-21.25 ± 3.88-13.15 ± 3.95-17.20 ± 2.78-20.15 ± 3.54
Statistical analysis
  • Any Remibrutinib vs Placebo · MMRM · p = 0.575 (one-sided p-value) · Mean difference (final values): 0.71 · 95% CI -6.75 to 8.16Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.294 (one-sided p-value) · Mean difference (final values): -1.98 · 95% CI -9.22 to 5.27Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.450 (one-sided p-value) · Mean difference (final values): -0.50 · 95% CI -8.40 to 7.41Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.913 (one-sided p-value) · Mean difference (final values): 6.02 · 95% CI -2.74 to 14.78Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.722 (one-sided p-value) · Mean difference (final values): 2.59 · 95% CI -6.16 to 11.34Difference (Any remibrutinib - Placebo)
  • Any Remibrutinib vs Placebo · MMRM · p = 0.241 (one-sided p-value) · Mean difference (final values): -2.86 · 95% CI -10.96 to 5.24
  • Any Remibrutinib vs Placebo · MMRM · p = 0.742 (one-sided p-value) · Mean difference (final values): 2.95 · 95% CI -6.09 to 11.99Difference (Any remibrutinib - Placebo)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.18 · 95% CI -8.28 to 7.91Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -0.65 · 95% CI -8.87 to 7.58Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): 0.10 · 95% CI -9.28 to 9.48Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -4.40 · 95% CI -14.71 to 5.90Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -12.1 · 95% CI -22.47 to -1.77Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -6.25 · 95% CI -16.00 to 3.50Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
  • Remibrutinib 100 mg qd vs Remibrutinib 100 mg Bid · MMRM · Mean difference (final values): -8.10 · 95% CI -19.16 to 2.96Difference (remibrutinib 100 mg qd - remibrutinib 100 mg bid)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

Number of participants with TEAEs and serious TEAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as TEAEs. TEAEs are defined as adverse events that started after the first dose of study medications or adverse events present prior to start of double-blind treatment but increased in severity. The number of participants in each category is reported in the table.

Time frame:
From first dose of study treatment up 30 days after last dose (Week 29)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsRemibrutinib 100 mg BidRemibrutinib 100 mg qdPlacebo
TEAE222120
Study drug-related TEAE1089
Serious TEAE111
SecondaryMaximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Reported as:
Mean · ng/mL
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4
ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 4183 ± 82.5225 ± 154
SecondaryMaximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Cmax is defined as the maximum (peak) observed blood concentration following a dose.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Reported as:
Mean · ng/mL
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24
ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Maximum Observed Blood Concentration (Cmax) of Remibrutinib at Week 24224 ± 202169 ± 77.9
SecondaryTime to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 4

Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Reported as:
Median · hours
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 4
hoursRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 41.00 (0.500 to 3.00)1.00 (0.500 to 4.00)
SecondaryTime to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 24

Remibrutinib was determined in whole blood by a validated LC-MS/MS method with a LLOQ of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. Tmax is defined as the time to reach maximum (peak) blood concentration following a dose.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Reported as:
Median · hours
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 24
hoursRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Time to Reach Maximum Observed Blood Concentration (Tmax) of Remibrutinib at Week 241.00 (0.500 to 3.00)1.00 (0.500 to 3.08)
SecondaryArea Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Reported as:
Mean · h*ng/mL
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4
h*ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 4569 ± 3111020 ± 700
SecondaryArea Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUCtau is defined as the area under the blood concentration-time curve calculated/extrapolated to the end of a dosing interval (tau) at steady-state. Tau was 24 hours for the qd dosing group and 12 hours for the bid dosing group. For the calculation of AUCtau, the pre-dose concentrations at Week 4 and Week 24 were duplicated as 24 hours and 12 hours concentrations for the qd and bid groups, respectively. The linear trapezoidal method was used for AUCtau calculation.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Reported as:
Mean · h*ng/mL
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24
h*ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Area Under the Blood Concentration-time Curve Within a Dosing Interval (Tau) at Steady-state (AUCtau) of Remibrutinib at Week 24670 ± 380636 ± 306
SecondaryArea Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Reported as:
Mean · h*ng/mL
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4
h*ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 4351 ± 169393 ± 207
SecondaryArea Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. AUC0-4h is defined as the area under the blood concentration-time curve from time zero to 4 hours post-dose, which was the last sampling time. The linear trapezoidal method was used for AUC0-4h calculation.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Reported as:
Mean · h*ng/mL
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24
h*ng/mLRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Area Under the Blood Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4h) of Remibrutinib at Week 24420 ± 259317 ± 144
SecondaryElimination Half-life (T1/2) of Remibrutinib at Week 4

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 4
Reported as:
Mean · hours
Elimination Half-life (T1/2) of Remibrutinib at Week 4
hoursRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Elimination Half-life (T1/2) of Remibrutinib at Week 43.08 ± 0.9983.86 ± 2.28
SecondaryElimination Half-life (T1/2) of Remibrutinib at Week 24

Remibrutinib was determined in whole blood by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1.0 ng/mL. Pharmacokinetic (PK) parameters were calculated based on remibrutinib blood concentrations by using the actual recorded sampling times and non-compartmental methods with Phoenix WinNonlin (version 8 or higher). Concentrations below the LLOQ were treated as zero. T1/2 is defined as the time taken for the blood concentration, as well as the amount of the drug in the body, to fall by one-half.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours post-dose at Week 24
Reported as:
Mean · hours
Elimination Half-life (T1/2) of Remibrutinib at Week 24
hoursRemibrutinib 100 mg BidRemibrutinib 100 mg qd
Elimination Half-life (T1/2) of Remibrutinib at Week 243.15 ± 0.9073.88 ± 1.95

Adverse events

Collected over From first dose of study treatment up 30 days after last dose (Week 29). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remibrutinib 100 mg Bid0/24 (0%)1/24 (4.2%)15/24 (62.5%)
Remibrutinib 100 mg qd0/25 (0%)1/25 (4%)12/25 (48%)
Any Remibrutinib0/49 (0%)2/49 (4.1%)27/49 (55.1%)
Placebo0/24 (0%)1/24 (4.2%)17/24 (70.8%)
Total0/73 (0%)3/73 (4.1%)44/73 (60.3%)
Most frequent serious events
Most frequent serious events
EventRemibrutinib 100 mg BidRemibrutinib 100 mg qdAny RemibrutinibPlaceboTotal
COVID-19 pneumoniaInfections and infestations1/240/251/490/241/73
PneumoniaInfections and infestations0/240/250/491/241/73
Herpes zosterInfections and infestations0/241/251/490/241/73
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRemibrutinib 100 mg BidRemibrutinib 100 mg qdAny RemibrutinibPlaceboTotal
HeadacheNervous system disorders1/243/254/495/249/73
NauseaGastrointestinal disorders4/241/255/492/247/73
LeukopeniaBlood and lymphatic system disorders0/240/250/493/243/73
LymphopeniaBlood and lymphatic system disorders0/240/250/493/243/73
FatigueGeneral disorders3/240/253/492/245/73
NasopharyngitisInfections and infestations2/241/253/493/246/73
Upper respiratory tract infectionInfections and infestations3/240/253/492/245/73
NeutropeniaBlood and lymphatic system disorders1/241/252/492/244/73
Abdominal distensionGastrointestinal disorders0/240/250/492/242/73
DiarrhoeaGastrointestinal disorders2/240/252/491/243/73

Baseline characteristics

Age, Continuous
Age, Continuous(years)Remibrutinib 100 mg BidRemibrutinib 100 mg qdPlaceboTotal
Mean49.5 ± 15.2154.8 ± 10.5151.0 ± 13.9451.8 ± 13.34
Sex: Female, Male
Sex: Female, Male(Participants)Remibrutinib 100 mg BidRemibrutinib 100 mg qdPlaceboTotal
Female24242371
Male0112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Remibrutinib 100 mg BidRemibrutinib 100 mg qdPlaceboTotal
Asian77721
White17171650
Unknown0101
Black or African American0011
08

Study locations

26 sites
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Woodville, South Australia 5011, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Sofia, 1612, Bulgaria
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Glostrup, 2600, Denmark
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46010, Spain
  • Novartis Investigative Site
    Vigo, Pontevedra 36200, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Taichung, Taiwan ROC 40201, Taiwan
  • Novartis Investigative Site
    Kaohsiung, 81346, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taichung, 40705, Taiwan
  • Novartis Investigative Site
    Liverpool, L9 7AL, United Kingdom
  • Novartis Investigative Site
    Swindon, SN3 6BB, United Kingdom
  • Novartis Investigative Site
    Tyne And Wear, NE29 8NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Nov 2021, 28 months.

Results were first posted in Dec 2022, 1 year after primary completion. A results delay was requested in Aug 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 29, 2019
StartActual
Jul 12, 2019
Primary completionActual
Nov 23, 2021
CompletionActual
Nov 23, 2021
Results delay requested
Aug 23, 2022
Results first posted
Dec 20, 2022
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04035668
Responsible party
Sponsor
First posted
Jul 29, 2019
Start date
Jul 12, 2019
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Results posted
Dec 20, 2022
Last update
Jan 30, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion